GCTK vs. PAVM, MBOT, CTSO, ICCM, LUCD, XAIR, NUVO, AMIX, DRIO, and DXR
Should you be buying GlucoTrack stock or one of its competitors? The main competitors of GlucoTrack include PAVmed (PAVM), Microbot Medical (MBOT), Cytosorbents (CTSO), IceCure Medical (ICCM), Lucid Diagnostics (LUCD), Beyond Air (XAIR), Holdco Nuvo Group D.G (NUVO), Autonomix Medical (AMIX), DarioHealth (DRIO), and Daxor (DXR). These companies are all part of the "surgical & medical instruments" industry.
GlucoTrack (NASDAQ:GCTK) and PAVmed (NASDAQ:PAVM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.
In the previous week, GlucoTrack and GlucoTrack both had 2 articles in the media. GlucoTrack's average media sentiment score of 1.43 beat PAVmed's score of 0.93 indicating that GlucoTrack is being referred to more favorably in the media.
10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 17.7% of GlucoTrack shares are owned by insiders. Comparatively, 12.6% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
GlucoTrack has higher earnings, but lower revenue than PAVmed. GlucoTrack is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.
GlucoTrack has a net margin of 0.00% compared to PAVmed's net margin of -2,037.67%. PAVmed's return on equity of 0.00% beat GlucoTrack's return on equity.
GlucoTrack has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500. Comparatively, PAVmed has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.
PAVmed has a consensus target price of $21.00, indicating a potential upside of 1,348.28%. Given PAVmed's higher possible upside, analysts plainly believe PAVmed is more favorable than GlucoTrack.
PAVmed received 201 more outperform votes than GlucoTrack when rated by MarketBeat users.
Summary
PAVmed beats GlucoTrack on 9 of the 14 factors compared between the two stocks.
Get GlucoTrack News Delivered to You Automatically
Sign up to receive the latest news and ratings for GCTK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GCTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GlucoTrack Competitors List
Related Companies and Tools
